Carlsmed (CARL) Liabilities and Shareholders Equity (2024 - 2026)

Carlsmed (CARL) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $118.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $118.8 million; the trailing twelve-month figure through Mar 2026 stood at $437.0 million (up 743.28% YoY), and the FY2025 full-year result was $130.1 million, up 151.08% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $118.8 million, down from $130.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $134.9 million in Q3 2025 and bottomed at $51.8 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $118.8 million (2026), against an average of $97.8 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 151.08% in 2025, while the deepest fall reached 151.08% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $51.8 million in 2024, then soared by 151.08% to $130.1 million in 2025, then slipped by 8.72% to $118.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $118.8 million (Q1 2026), $130.1 million (Q4 2025), and $134.9 million (Q3 2025), per Business Quant data.

Peer Comparison